This Alzheimer's Drug Slashes Symptoms by 30 Percent, New Study Says
bestlifeonline.com
A new Alzheimer's drug, lecanemab, has been shown to reduce symptoms by nearly 30 percent, a phase 3 trial has concluded.

Eisai and Biogen announced the results from an 18-month, phase 3 clinical trial for the Alzheimer’s drug lecanemab. Classified as an anti-amyloid antibody treatment, lecanemab slowed the rate of cognitive decline by 27 percent in early stage Alzheimer’s patients, the data showed.